Lv21
185 积分 2021-07-14 加入
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
2小时前
已完结
Strategies following failure of CAR-T-cell therapy in non-Hodgkin lymphoma
9天前
已完结
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial
16天前
已完结
Is blinatumomab now standard of care consolidation for patients with ALL?
16天前
已关闭
Eltrombopag plus diacerein vs. eltrombopag in patients with ITP: a multicenter, randomized, open-label, phase 2 trial
23天前
已关闭
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial
1个月前
已完结
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development
1个月前
已完结
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia
1个月前
已完结
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia
1个月前
已关闭
Hematopoietic stem cell transplantation activity in China 2022–2023. The proportions of peripheral blood for stem cell source continue to grow: a report from the Chinese Blood and Marrow Transplantation Registry Group
1个月前
已完结
皖公网安备34019202002308
